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ABSTRACT
Purpose To predict precision and other performance character-
istics of chromatographic purity methods, which represent the most
widely used form of analysis in the biopharmaceutical industry.
Methods We have conducted a comprehensive survey of purity
methods, and show that all performance characteristics fall within
narrow measurement ranges. This observation was used to develop
a model called Uncertainty Based on Current Information (UBCI),
which expresses these performance characteristics as a function of the
signal and noise levels, hardware specifications, and software settings.
Results We applied the UCBI model to assess the uncertainty of
purity measurements, and compared the results to those from
conventional qualification. We demonstrated that the UBCI model
is suitable to dynamically assess method performance characteristics,
based on information extracted from individual chromatograms.
Conclusions Themodel provides an opportunity for streamlining
qualification and validation studies by implementing a “live valida-
tion” of test results utilizing UBCI as a concurrent assessment of
measurement uncertainty. Therefore, UBCI can potentially miti-
gate the challenges associated with laborious conventional method
validation and facilitates the introduction of more advanced analyt-
ical technologies during the method lifecycle.
KEY WORDS live validation . method precision . purity
methods . uncertainty, UBCI
INTRODUCTION
The safety and efficacy of biopharmaceuticals is controlled
by measurements of their quality attributes. To measure
these attributes for protein pharmaceuticals, a set of ana-
lytical methods are developed that have to meet the
requirements specified by the International Conference
on Harmonization (ICH) guideline Q6b, “Specifications:
Test procedure and acceptance criteria for biotechnolog-
ical/biological products” (1). The largest category of
methods is made up of purity (and impurity) methods
used to determine the relative abundance (normalized
concentration) of defined attributes. The term purity and
relative abundance will be used interchangeably through-
out the manuscript. Typically, these methods involve chro-
matographic and electrophoretic separations. Because of
the molecular complexity of biopharmaceuticals, the
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purity of protein drugs is generally assessed by a larger
number of analytical methods relative to those used for
purity determination of small molecule drugs (2). There-
fore, the measurement of purity and the assessment of
uncertainty of the test results play important roles for
the biotechnology industry in controlling product quality.
The appraisal of the uncertainty of results is performed
during formal method validation.
Since the necessity of method validation has been rein-
forced by a variety of national and international regula-
tions (3–6) industry practitioners fully understand the
importance of method validation as a means of ensuring
the scientific validity of results. However, existing guid-
ance is subject to user interpretation leading to the poten-
tial for confusion when it comes to carrying out the
validation exercise. However, numerous articles have been
published to provide scientific justification for the impor-
tance of this activity, and to alleviate the vagueness of
these regulations (7–13). The most frequently referenced
publication is the ICH guideline Q2R1, “Validation of
analytical methods: text and methodology” (6). This doc-
ument covers validation activities targeted at product reg-
istration; hence, this guidance is specifically applicable to
commercial products at the time of the product develop-
ment lifecycle when the marketing application is submitted
to the regulatory authorities. As a matter of industry
practice, many, if not most, practitioners carry out
Q2R1 compliant method validation activities to enable
use of the validated methods for the testing of the process
validation lots. While there is no specific guidance on
method validation for earlier stages of product develop-
ment, regulatory expectations and industry practices have
evolved to provide assurance of acceptable method per-
formance in earlier development stages. The generally
accepted term for these pre-commercial activities is meth-
od qualification (9,14), but the scope of the qualification,
timing with respect to the various stages of product de-
velopment, and the relationship of qualification to valida-
tion activities has not been consistently delineated or
practiced. In fact, method qualification is not mentioned
in available guidelines, so it is difficult to define its scope
and significance, although it is clear that both qualifica-
tion and validation activities should be carried out by
qualified (i.e.; properly trained) personnel using qualified
instrumentation that has been shown to be fit for its
intended purpose.
As a matter of industry practice, most practitioners carry
out qualification activities to enable release and stability
testing of GMP lots used in the clinic at all times prior to
the availability of fully validated methods around the time of
the process validation lots, as described above. Typical
validation/qualification studies include evaluation of the
following performance characteristics: precision (repeatability
and intermediate precision), specificity, accuracy, detection
limit (DL), quantification limit (QL), linearity and range. In
many cases, numerous sample types are subject to these stud-
ies. Therefore, qualification and/or validation studies are very
labor intensive, and often can create a significant bottleneck in
the analytical lifecycle, which, in turn, significantly contributes
to the cost of development and the cost of quality.
The uncertainty of results is a parameter that describes a
range within which the measured value is expected to lie (15).
Intuitively, we associate this parameter with precision. There-
fore, method precision has been viewed as the most important
performance characteristic relevant to establishing specifications
(16), method transfer requirements (17), method robustness (12),
assessment of process variability, etc. (18,19).Typically, method
precision has been assessed from replicate analyses of the same
sample. The work of Hayashi and Matsuda on FUMAI theory
(20–25) demonstrated that the precision of chromatographic
methods can be predicted from noise and the height and width
of the signal (peak). However, due to the complexity associated
with the required Fourier transformation of chromatograms
and the parameterization of the power spectrum called for in
implementation of this theoretical construct to the determina-
tion of precision, the FUMAI theory approach has not been
widely applied. Similarly, attempts have been made to predict
DL and QL based on chromatographic information (26–28);
however, other performance characteristics have not been
addressed.
In this manuscript, we present a new approach to assessing
the uncertainty (performance characteristics) of purity analysis
using a more holistic approach which we call Uncertainty
Based on Current Information (UBCI). The model allows
for real-time assessment of all performance characteristics
using the results of the specific separation of interest. A fun-
damental, underlying principle of this approach recognizes
that the execution of a purity method is always associated with
specific circumstances; therefore, uncertainty about generated
results needs to account for both the operational conditions of
the method and the hardware. It is important to note that
historical qualification/validation approaches do not take this
fundamental principle into account, such that performance
drift may occur over time due to hardware differences and
even due to differences in analyst skill levels, such that the
uncertainty of results obtained early in the product lifecycle
may not be fully applicable to results obtained later following
product commercialization.
We will show that signal and noise levels, instrument
settings and software settings can be linked directly to all
method performance characteristics. Such simplification/
generalization makes it easy to implement this procedure
in a daily operation, and can provide a valuable live assess-
ment of uncertainty instead of extrapolating uncertainty
from historical qualification/validation studies. As noted
above, application of historical validation data always begs
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a question about the relevance of these data to the current
experimental situation, and sometimes requires investiga-
tion, which can delay the approval of results. This new
approach, therefore, has the capability of providing not only
simplicity, but also a greater level of assessment of the data
validity relative to current practices. We view this as an
important step toward ‘live validation’ of purity methods.
MATERIALS AND METHODS
Qualification for Purity Methods
To demonstrate the suitability of the methods for their
intended purposes, Amgen has established an internal guide-
line to govern and streamline the method qualification process.
System suitability: Each set of experiments has be preceded
with three and bracketed (ended) with two injections of the
reference material to satisfy requirements of system suitability
(4). Parameters of system suitability included resolution and
reproducibility requirement for the reference standardmaterial
used by the method. Blank injections were added occasionally.
A series of experiments was designed to evaluate the meth-
od performance against qualification target expectations. The
performance characteristics that were addressed for purity
methods included specificity, linearity, precision, accuracy,
range, DL, andQL. Specificity was determined by comparing
the sample and sample matrix blank to assure that no signif-
icant interference from the sample matrix with reported peaks
was present. In addition, carryover and recovery were calcu-
lated to measure the specificity of the method.
% carryover was calculated using the equation below:
Carryoverð%Þ ¼ BS  BB
AS
 100% ð1Þ
where Bs is the total integrated peak area in blank injected
after sample, BB is the total integrated peak area in blank
injected before sample, and AS is the total integrated peak
area in sample.
Protein recovery and % recovery were calculated using
the equations below (29,30):




where A is the total peak area in mAU*sec, F is the flow rate
in mL*min−1, ε is the extinction coefficient at detection
wavelength, (or 280 nm) in AU*mL*mg−1*cm−1, and l is
the path length of flow cell in cm.
Recovery ¼ Protein recovered=Protein injectedð Þ  100%
ð3Þ
The initial theoretical extinction coefficient for proteins
was calculated from the amino acid composition (31). An
experimental extinction coefficient was also determined us-
ing amino acid analysis. If the experimental value agrees
within 10% of the theoretical value then, theoretical extinc-
tion coefficient was used throughout the studies. Otherwise,
experimental extinction coefficient was used. In all cases, the
protein samples were highly purified, with less than
100 ppm of host cell protein impurities present.
Linearity of the method was established by calculating the
coefficient of determination (R2) to correlate the total peak
area with protein load from 50% to 150% of target load.
Linearity of minor species was evaluated by performing a
blending study with minor species-enriched samples to show
that the minor species behaved similarly as the main product.
Precision was assessed for both repeatability and intermediate
precision. Repeatability was determined by calculating the %
Relative Standard Deviation (RSD) of 3 determinations of the
5 concentrations within the linear range.. Intermediate preci-
sion was evaluated by calculating the % RSD of 3 determi-
nations of target load from 5 different experiments,
accounting for differences from the day of experiment, ana-
lyst, equipment and column/capillary lot. Accuracy was
expressed as 100 × (1– slope), in which slope was obtained
by regression analysis plotting % main peak vs.% target load.
Range was the low and high end of protein concentrations of
the linearity study. Limit of detection (DL) and limit of quan-
titation (QL) were estimated using the statistical approach
described previously (32) Execution of all qualification experi-
ments required at a minimum 101 injections, which can be
completed in five sequences.
Purity Assessment by SE-HPLC, CEx-HPLC, and rCE-SDS,
Peptide Map and Glycan Map
SE-HPLC (Size Exclusion HPLC): the protein sample was
loaded SE-HPLC column (TSK-GEL G3000SWXL,
7.8 mm×300 mm, 5 μm particle size, Tosoh Bioscience),
separated isocratically with phosphate buffer containing
sodium chloride salt, and the eluent was monitored by UV
absorbance. Samples were injected neat without prior
dilution.
CEx-HPLC (Cation Exchange HPLC): the charge var-
iants of mAbs were separated on a cation exchange column
(Dionex WCX-10, 4.0 mm×250 mm, 10 μm particle size,
Dionex) by increasing the salt concentration (hereby the
ionic strength of mobile phase). The eluent was monitored
by measuring the UV absorbance. For analysis of mAbs,
mobile phase A was based on a MES buffer, mobile phase B
contained MES buffer with NaCl salt. Samples were
injected neat without prior dilution.
rCE-SDS (reduced Capillary Electrophoresis in SDS):
rCE-SDS was performed on a Beckman Coulter
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ProteomeLab PA800 CE. The protein was reduced with β-
mercaptoethanol. The reduced protein species were bound
to SDS, an anionic detergent, and electrokinetically injected
into a bare fused silica capillary. The SDS coated protein
species were separated with SDS gel buffer (15 kV for
30 min), and detected with UV at 220 nm by a photodiode
array (PDA) detector.
Peptide maps: Peptide mapping is an analytical method
in which the test protein sample is first digested into peptides
by a site-specific endoproteinase. The peptides are then
resolved by reversed phase HPLC to generate a pattern of
peaks. Samples were digested at 37°C for 16 h with a 1:100
enzyme to substrate ratio using Lys-C endoproteinase.
50 μg of digested protein was then separated using a 0.1%
TFA in water/acetonitrile gradient using a C8 reversed-
phase HPLC column. During method development, in
line mass spectrometer was used to confirm identity of
peptides (33).
Glycan map:. The glycans on the antibody were released
by adding 1 μL of PNGase F to every 100 μg of protein.
The released glycans were labeled by adding 10 μL labeling
reagent (0.35M 2AB, 1 M NaCNBH3 in 70:30 (vol:vol)
DMSO:acetic acid), and the reaction was allowed to pro-
ceed for 2 h at 65°C. After the reaction, the excess labeling
reagent was removed by an S-cartridge (QA-Bio). To ana-
lyze the 2AB labeled glycans, the mixture was separated on
a C18 reversed-phase column (3 μm, 4×250 mm, Thermo
Scientific, Waltham, MA, USA). The mobile phase was a
mixture of 0.1% acetic acid in water (A) and 0.1% acetic
acid in 10:90 acetonitrile:water (B). The gradient was from
30% B to 75% B in 135 min. The flow rate was 0.2 mL/
min. The eluate was monitored on a fluorescence detector
with excitation at 330 nm, and emission at 420 nm. RP-
HPLC was performed using an Agilent (Santa Clara, CA,
USA) Series 1100 binary pump system directly coupled to
the mass spectrometer. During method development, in line
mass spectrometer was used to confirm identity of glycans
(33–35).
Instruments
Experiments described in this manuscript were performed
using Agilent 1100, Agilent 1290 and Waters HPLC systems
equipped with diod array detector (DAD) or Variable
Wavelength Detector (VWD). Capillary Electrophoresis
(CE) experiments were performed on a Beckman PA 800
instrument.
Mass spectrometry experiments were conducted using a
linear ion trap mass spectrometer (LTQ, Thermo Electron),
equipped with an ESI source coupled directly to the HPLC
instrument (33–35). All experiments were performed in the
positive ion mode. Typically, LC/MS and tandem MS
experiments were conducted using a spray voltage of
3.5 kV and a capillary temperature of 250°C. For the
generation of tandem mass spectra, the parent ions were
selected with an m/z window of 10, and the relative collision
energy was set to 35%.
All data were acquired on qualified instrumentation op-
erated by trained analysts.
RESULTS
Development of the UBCI model involved three major
steps: (1) an examination of historical in-house data from
several qualification studies performed for different types of
chromatographic and electrophoretic separations; (2) a se-
ries of repeatability tests signifying intrinsic variability of
measured method precision and (3) a thorough evaluation
of the signal and noise in chromatographic systems. Follow-
ing the development of the model as it relates to method
precision, which is a central feature of the model, we ex-
tended the model to all the performance characteristics of
the method. Finally, we applied the model to a single chro-
matogram to assess the uncertainty of results, and compared
it with historical results of qualification as a test of the
validity of the model.
Survey of Qualification Studies
Over the last several years, we have collected method per-
formance characteristic data, as prescribed by the ICH
Q2R1(6) guideline, for approximately 90 methods applied
to as many as 20 different protein pharmaceuticals. Multiple
sample types were often investigated for the same product.
Examples of chromatograms and an electrophoregram for
SE-HPLC, CEx-HPLC and CE-SDS methods, respectively,
are shown in Supplementary Material Figure S1.
We retrospectively evaluated the data set and found that
the values of many performance characteristics fall into very
narrow ranges. An example of the statistical evaluation for
these performance characteristics is presented in Table S1,
Because data are not normally distributed, we have shown
mean, median, range and 90 percentile. For certain sample
types, we have performed an abbreviated method quali-
fication (for which the evaluation of all performance char-
acteristics/parameters was not evident or required) that
resulted in an apparent incomplete data set, and this is
reflected in a different “n” values for different performance
characteristics.
The repeatability and intermediate precision data for the
SE-HPLC, CEx-HPLC, and CE-SDS methods is shown
graphically in Fig. 1. Repeatability refers to the ability of
the method to generate identical results for the same sample
within a short time interval. Intermediate precision refers to
the ability to replicate measurements by someone else, in a
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different laboratory, and/or different time interval. The
graph indicates a linear relationship between repeatability
and intermediate precision expressed in the form of RSD,
with a slope approaching unity. However, for a given value
of repeatability, the spread for intermediate precision is
approaching one order of magnitude (note the log-log scale
of the graph).Three distinct clusters are evident. The
bottom-left cluster is represented by the precision of the
main peak from SE methods. The middle cluster corre-
sponds to precision of the main peak from ion-exchange
and CE methods. The upper-right cluster represents the
precision for minor peaks from all three methods. The level
of the minor peaks ranges from a fraction of a percent in SE-
HPLC methods to approximately 10% in CEx-HPLC. This
close correlation between repeatability and intermediate
precision could be a result of standardization of equipment
to one or two brands to reduce the complexity of method
transfer. This shows that performing both repeatability and
intermediate precision studies may have limited value in
exploring method performance.
The data shown in Fig. 1 corroborates the Horwitz
relationship between the concentration of analyte and the
precision of the method expressed in RSD (36,37). Minor
peaks, for which concentration is one or two orders of
magnitude lower than the main peak, showed significantly
higher RSD than the main peak. However, the observed
relationship may not strictly follow the canonical rule that a
change in concentration of two orders of magnitude corre-
sponds to a two-fold change in precision (38).
Repeatability
We designed experiments to evaluate the consistency in the
determination of method precision (repeatability) for the
same sample. The sample was analyzed using the same
instrument, by the same analyst, on two different days. To
maximize information obtained from a limited number of
experiments, we evaluated the output of two different
methods with well resolved multiple peaks: peptide and
glycan maps. Large amounts of peptide digest and 2AB
derivatized glycans were prepared. The same sample was
used in all experiments described below. The peptide maps
show 9 peaks, and were monitored using a UV detector at
215 nm. Additionally, the chromatograms for peptide maps
were acquired at different acquisition rates to introduce
variability in the form of a different level of observable
noise. Glycan maps were used to monitor 16 well resolved
glycan forms, and were monitored using a fluorescence
detector signal. Figure S2 shows examples of the peptide
and glycan maps. Table S2 summaries the overall design of
the experiment.
The experiment was designed to test the hypothesis that
there should be no significant difference between the meth-
od repeatability of two sets of measurements generated on
two different days. We used a statistical F-test to evaluate
this hypothesis (15). For this hypothesis to be true, the ratio
of the two sample variances should be less than the critical
F-values defined by two values of degrees of freedom. The
variance of purity measurements for individual peaks
(analytes) of the peptide map was calculated from analysis
of triplicate experimental runs on both days. For the peptide
map, the degrees of freedom for both the numerator and the
denominator of 2 for the F-test resulted in an F-critical0
19.0 at a 95% confidence level. For glycan maps, the vari-
ance for individual peaks was calculated from 3 replicates on
day 1 and 9 replicates on day 2, corresponding to degrees of
freedom of 2 and 8, respectively. In this situation, F-critical
will assume values of 4.5 and 19.4, respectively, depending
on which value of variance was used as the denominator.
The results of these experiments and the value of the calcu-
lated F-critical are shown in Table I.
The results show that precision measurements for certain
pairs of experiments were significantly different, and in 12%
of cases (4 out of 27 for the peptide map and 1 out 16 for the
glycan map) the ratio of variances exceeded the value of the
corresponding F-critical at the 95% confidence level. It can
be concluded that in certain situations a significant differ-
ence does exist between precision of purity for certain peaks
(analytes) measured by the same method on two different
days. 60% of F test results had the ratio of two variances
greater than 3 in Group A and 36% of them had that ratio
in Group B. 19% of the experiment results had the ratio of
two variances greater than 10 in Group A and 25% of them
in Group B (21% overall). The F test was conducted based
on limited sample sizes, and may have an imperfect statisti-
cal power. However, this is a practically significant indica-
tion that the assay variability for the same sample is not
constant over multiple days, even when the assay is per-
formed on the same instrument and by the same analyst. It
appears that a significant variability of precision is an intrin-































Fig. 1 Relationship between repeatability and intermediate precision for
three purity methods (SE-HPLC, CEx-HPLC, and rCE-SDS). Each point of
the graph represents different protein analyte. Data were obtained in
qualification experiments.
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Examination of Noise in Chromatographic Systems
Stimulated by the work of Hayashi and Matsuda on FUMI
theory (22,25), which relates the stochastic properties of back-
ground noise to method precision, we turned our attention to
chromatographic noise (39,40) with the intention of finding an
explanation of these intriguing observations regarding precision,
specifically, a significant variability in the determination of pre-
cision for individual analytes, and a close relationship between
repeatability and intermediate precision. The FUMI theory
requires parameterization of the Fourier transformed noise
(power density spectrum) to compute the value of the noise
parameters for the chromatographic measurements (22,25).
However, the power density spectrum showed distinct regular
features thatmade the spectrum difficult to parameterize per the
Hayashi and Matsuda method. The complexity of the power
spectrum can be attributed to the proprietary manipulation of
the signal by hardware and software manufacturers.
Many commercial chromatographic software packages
can extract and report information about the noise in dif-
ferent ways. The most popular are peak-to-peak noise and
ASTM noise (which is based on ASTM standard E 685–93)
(41). Peak-to-peak noise is a transient measure of the ampli-
tude of the noise, while the ASTM standard provides an
averaged value of the noise. Figure 2 shows the change of
the amplitude of peak-to-peak and ASTM noise as a func-
tion of the acquisition rate, where the data was extracted
uniformly from chromatograms of the peptide maps. The
graph illustrates a linear increase of the observed noise with
an increase of the acquisition rates in the range of 0.25 to
20 Hz. Parallel regression lines indicate a linear relationship
between peak-to-peak noise and ASTM noise. A similar
general relationship has been observed for more than 200
noise measurements extracted from a variety of chromato-
grams (data not shown). It appears that the reported peak-
to-peak noise is roughly 1.3-1.5 times larger than the ASTM
Table I Results of Experiments Comparing Method Repeatability Using an F Test. (Red Font Indicates Non-Passing Values)
A-Peptide map (3 replicates, 2 degrees of freedom for both the numerator and denominator of the F-test, Fcrit019.0)
1 Hz 5 Hz 20 Hz
Variance Fratio Variance Fratio Variance Fratio
Peptide# Day 1 Day2 Day 1 Day 2 Day 1 Day 2
1 5.78E-07 8.19E-07 1.42 2.25E-07 6.31E-07 2.81 5.83E-07 3.07E-08 18.95
2 1.67E-08 5.65E-09 2.96 1.36E-08 6.42E-08 4.72 2.52E-08 1.60E-07 6.36
3 1.09E-08 1.22E-09 8.98 4.66E-10 2.49E-08 53.50 1.08E-09 5.49E-08 50.76
4 2.53E-09 5.33E-09 2.10 4.01E-09 1.84E-08 4.59 3.15E-09 2.32E-08 7.37
5 8.12E-08 1.45E-07 1.78 3.76E-08 3.55E-08 1.06 3.60E-09 2.26E-08 6.27
6 2.34E-08 2.76E-08 1.18 1.29E-08 3.46E-08 2.69 6.22E-10 5.00E-08 80.36
7 6.66E-08 1.95E-08 3.42 1.19E-09 6.29E-08 53.02 1.61E-08 1.13E-07 7.03
8 8.60E-09 3.77E-08 4.38 2.59E-09 9.90E-09 3.82 9.94E-09 1.55E-08 1.56
9 4.29E-08 7.36E-08 1.72 2.75E-07 3.19E-07 1.16 7.07E-07 2.18E-07 3.24
B, Glycan map ( 3 or 9 replicates, correspond to 2 and 8 degree of freedom respectively)
Glycan # 3 repl./Day1 9 repl. Day2 F ratio F crit
1 6.80E-10 1.61E-09 2.37 19.4
2 7.66E-10 7.32E-09 9.56 19.4
3 4.08E-10 2.50E-10 1.63 4.5
4 1.76E-09 1.18E-09 1.49 4.5
5 7.89E-09 4.19E-09 1.88 4.5
6 3.71E-09 4.53E-08 12.21 19.4
7 1.60E-08 1.40E-07 8.75 19.4
8 2.31E-08 5.54E-08 2.40 19.4
9 1.39E-07 1.47E-07 1.06 19.4
10 1.82E-10 2.67E-09 14.68 19.4
11 1.02E-08 1.17E-08 1.15 19.4
12 1.20E-08 9.81E-08 8.16 19.4
13 8.44E-09 1.77E-08 2.09 19.4
14 1.65E-08 2.04E-07 12.38 19.4
15 7.09E-08 5.28E-08 1.34 4.5
16 6.56E-08 3.63E-06 55.33 19.4
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noise, which is consistent with the definition of ASTM noise
providing an “averaged” value of the noise instead of the
“local” peak-to-peak noise that can be transiently
overestimated.
Signal to Noise Ratio and Precision
Inspired by Dolan’s rule of thumb (42),RSD  50S=N , we have
explored the connection between method precision and the
signal to noise (S/N ) ratio. Figure 3 shows the experimental
affiliation (in log-log scale) between RSD of the methods
and (S/N)−1 for more than 200 chromatographic peaks
(from SE-HPLC, CEx-HPLC, peptide maps, and glycan
maps). The graph shows that the decrease in S/N ratio
results in the lower precision of the method (higher RSD).
For the same S/N ratio, the spread in the precision
approaches 3 orders of magnitude, indicating that factors
other than S/N ratio significantly influence the precision of
purity measurements.
Assessment of Precision for Purity Methods
Previous experiments indicated that the S/N ratio is not a
single factor influencing the precision of purity measure-
ments, which steered us toward the development of a more
comprehensive model of precision for purity measurements
that takes into account multiple sources of potential error as
well as other factors, described below.
Let us consider a chromatogram with two or more peaks,
as represented in Figure S3a.
The purity, relative abundance, (P1) of the first analyte
(component 1) will be expressed as a function of two inde-
pendent variables R1 and A1 as follows:
P1 ¼ A1R1 þ A1 ð4Þ
where A1, represents the area of the first component, and
R1 represents the area under all other peaks on the chro-
matogram (R10A2+A3 in Fig. S3). Relative abundance of
subsequent components can be expressed in an analogous
way. The variance of P1 can be approximated by the fol-
lowing equation (detailed proof can be found in the Supple-
mentary Material).
V ðP1Þ  EðA1Þ
2V ðR1Þ þ EðR1Þ2V ðA1Þ þ 3V ðA1ÞV ðR1Þ
EðA1 þ R1Þ4
ð5Þ
where E(A1) is the expected value for the area under peak 1
(A1), E(R1) is the expected value for the area of all peaks
except the peak of interest, A1, E(A1+R1) is the expected
value for the total area expressed as A1+R1, V(A1) is the
variance of A1, and V(R1) is the variance of R1.
Expected value can be derived through statistical analysis
of measured area under the peak and can be approximated
by averaging values of this random variable. The value
accounts for errors associated with the measurement.
If the A1 area is very small (A1<<R1), typically order of
magnitude smaller than R1 (equivalent to A1 less than 10%
of the total area), the above equation can be simplified.
V ðP1Þ  V ðA1Þ
EðR1Þ2
ð6Þ
Equations 5 and 6 show that the variance of purity
depends on variances and expectation values for the peak
area of analytes, where both statistics behave in an uncor-
related manner. This indicates that the precision of purity will
be influenced by the absolute amount of the injected
analyte.
y = 0.0063x + 0.0449
R² = 0.9697






















Fig. 2 Relationship between the level of noise (solid diamonds represent



















Fig. 3 Relationship between precision and S/N ratio for chromatographic
purity methods.
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The expected values of A1, R1, and A1+R1 can be
approximated by computing averaged values. Therefore, it
is critical to assess variances for A1 and R1. In our model, all
peaks are well resolved, and can be treated as independent
variables. Therefore, the variance of R1, can be expressed as
the sum of variance of individual peaks.
V ðR1Þ ¼ V ðA2Þ þ V ðA3Þ þ . . . ð7Þ
The true area under each individual peak can be
expressed as the area of the theoretical peak and a series
of independent errors impacting the measurements. We are
assuming that samples are analyzed without the introduc-
tion of preparation errors (e.g., dilution error)
A1 ¼ A01 þ EInj: þ EIntegration þ ENoise ð8Þ
where A01 is the theoretical area under the peak (constant for
the given sample, and does not account for any errors), EInj.
is the error of injection influencing the peak area, EIntegration is
the error of numerical peak integration, and ENoise is the
error of peak integration influenced by baseline noise.
Therefore, assuming that all the components are inde-
pendent
V ðA1Þ ¼ V ðInj:Þ þ V ðIntegrationÞ þ V ðNoiseÞ ð9Þ
Injection error (EInj.) is typically expressed in the form of
RSD by the instrument makers, and is generally listed in the
instrument specification table. Therefore, the variance of
injection can be expressed by the following equation
V ðInj:Þ ¼ ðA01Þ2  ðRSDInstr:Þ2 ð10Þ
where RSDInstr. 0 Instrument precision (injection precision)
taken from the instrument specifications.
The error of peak integration is related to the numerical
integration of the area under the peak, and constitutes a
broad family of algorithms for calculating the numerical
value of a definite integral. A large class of integration
algorithms can be derived by constructing interpolating
functions. The simplest method of this type is to let the
interpolating function be a constant function within the
integration subinterval, and is called the midpoint rule or
rectangle rule (43). Assuming that the shape of the chromato-
graphic peaks is described by a Gaussian function, the error
of integration, using the rectangular rules (Fig.S3b), can be
expressed by the following equation (43).









where w is the width of the integration domain (peak width
at the base in sec), V(w) is the variance of the integration
domain, which must be known or experimentally
determined, n is the number of points across the integration
domain of peak 1 (Fig. S3a), which can be expressed as n0
w n, n is the frequency of acquisition (points /sec), t is time,
and max f’(t) is the maximal value of the first derivative of the
function describing the peak shape. We assume that peaks
are described by Gaussian functions, for which maximal value
of the first derivative is at the deflection point one σ from the
apex; therefore






where A01 was described earlier as theoretical area under
peak 1 (constant for the given sample) and σ is the dispersion
(standard deviation) of the Gaussian distribution expressed
in the units of time domain.
Therefore, the variance of the numeric integration can be
expressed as:






 V ðwÞ ð13Þ
Different instrument makers may use different algo-
rithms, but application of the rectangular rules most likely
will approximate the upper bound of the numerical integra-
tion variance.
The third component contributing to the error in deter-
mination of the peak area is the noise of the system. Noise is
a low-level high frequency signal, and has the property that
when it is integrated over a longer period of time, it averages
to zero. Therefore, assuming that the baseline of integration
is accurately determined, the contribution of the noise to
peak area can be considered negligible. However, noise can
interfere with accurate determination of the baseline, which
can lead to a significant variability in the measured peak
area, as illustrated in Figure S3c. The same peak of the
analyte can be integrated differently, depending on the
“position” of the noise vs. the signal. Introduced integration
bias can be defined as extra area added or subtracted to the
theoretical area of the peak, depending on the (arbitrary)
established baseline. The maximum area added or sub-
tracted is a rectangle that can be defined as w × N, where
N represents the amplitude of the noise, and w represents
the width of the integration domain. Based on hypothesis
that the major contribution to noise is given by the photon
counting in the detector (44), we assume a Poisson distribu-
tion of the noise, which has a unique property that the
numerical value of variance is equal to the expected value.
Therefore,
V ðNoiseÞ ¼ V ðwN Þ ¼ EðwÞ2V ðN Þ þ EðN Þ2V ðwÞ þ V ðwÞV ðN Þ
¼ EðwÞ2EðN Þ þ EðN Þ2V ðwÞ þ V ðwÞEðN Þ
ð14Þ
Toward a Live Validation of Purity Methods 3411
Typically, V(w) is significantly smaller than the expected
value E(w); therefore, the second and third term in the
above equation will be much smaller than the first term,
and can be omitted, as follows:
V ðNoiseÞ  EðwÞ2EðN Þ ð15Þ
Combining together [10], [13], and [15], the maximal
value of variance of each individual peak can be expressed
by the following equation
V ðA1Þ  A01RSD




þ EðwÞ2EðN Þ ð16Þ
We do not know the exact value of A01 , but it can be
approximated with the averaged value of A1. Similarly,
expected value of noise, E(N) ,can be approximated with
the averaged value of ASTM noise. The value of dispersion
of chromatographic Gaussian peaks (σ) can be approximat-
ed from the average of peak width at the half height by using
the following relationship: σ0w/2.355 (45). Now, to com-
pute the variance of the purity determination, we will need
to return to equations 5 and 7, and substitute in their values
obtained from equation 16. In the special cases of small
minor peaks (<10%), equations 6 and 7 can be used. Vir-
tually all of the information that is needed to calculate the
precision of purity measurements can be extracted from the
current chromatogram; therefore, we call the developed
concept a model of Uncertainty Based on Current Informa-
tion (UBCI).
We applied the UBCI model to calculate the maximum
imprecision of purity measurements for individual peaks in
our methods: glycan and peptide maps. Glycan and peptide
maps were chosen because they show well resolved peaks
with wide ranges of intensity and peak width, which allows
for quick evaluation of the model. In the case of peptide and
glycan maps the term purity refers to relative abundance of
the particular peptide or glycan. As stated previously, pep-
tide maps were monitored using a UV detector, while for
glycan maps, we used a fluorescence signal. To introduce
additional variability in the form of a different level of
observable noise, we collected chromatograms at different
acquisition rates. Table S3a summarizes the design of the
experiment.
All measurements were performed in replicates, creating
an opportunity to calculate the precision using traditional
statistical methodology, and the prediction of maximal un-
certainty using the UBCI model.
First we calculated the variance of area under each
individual peak using equation 16, which requires knowl-
edge of the following variables: peak area, peak width at the
base (width of integration domain), peak width at the half
height, the level of baseline noise, the acquisition rate, and
the precision of injection for the HPLC instrument.
Replicate analyses were used to calculate the variance of
the integration domain (peak width at the base). The vari-
ability of the integration domain expressed in the form of
RSD showed a characteristic distribution (Fig. 4). Data
indicates that in 50% of the scenarios the RSD of the
integration domain is less than 1%; in 75% of the scenarios,
RSD of the integration domain is within 3%.
The expected values of all variables were approximated
from averages. We used ASTM noise provided by the
Agilent ChemStation software to approximate the ampli-
tude of the noise. The acquisition rate was extracted from
software settings embedded into the data files. The injection
volumes exceeded 5 μl in all experiments; therefore, the
imprecision of such injections should not exceed 0.5%
RSD, based on the HPLC specifications (46). In the next
step we used equation 7 to calculate the variance of com-
plementing peaks (sum of all peaks except peak of interest)
on the chromatogram, and finally we used equation 5 to
calculate the variance of the purity measurements for each
individual peak.
A total of 104 calculations and predications were con-
ducted. The observed variance for these measurements vs.
predicted uncertainty in the form of variance is shown in
Fig. 5. The results show that in all but a few cases, the
observed variance did not exceed the predicted maximal
variance, which is visualized by the fact that virtually all
points fall below the line with a slope equal to one. The two
points farthest away from the origin (Fig. 5) are associated
with the variance of peak 9 in the peptide map. The peak
was integrated very broadly (peak width at the base
exceeded 20 times peak dispersion), and in one case, (far-
thest point) variability of the integration domain was
approaching 40%. These results indicate that the uncertain-
ty of purity measurements can be controlled by integrating
















Peak width varabilty [%RSD]
Fig. 4 Distribution of the variance of the integration domain. Experiments
outlined in Table S3 were used in the analysis. Total of 206 analytes were
evaluated.
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In addition to the model system of peptide and glycan
maps, we applied the UBCI model to size exclusion and ion
exchange chromatographic separations. We applied this
analysis to the well resolved peaks. In the case of CEx-
HPLC, as exemplified in Figure S1, we omitted computing
precision for the basic peaks that are small and poorly
resolved. Six different protein products were evaluated,
including mAbs and fusion proteins. A total of 101 predic-
tions of precision were computed. The design of these
experiments is summarized in Table S3b. When plotted as
observed vs. predicted variances, the graph looks similar to
the results presented in Fig. 5 (data not shown), which
demonstrates the general utility of the UBCI model.
An alternative representation of all results (SE-HPLC,
CEx-HPLC, peptide and glycan maps) is presented in the
form of the distribution of the ratio of the predicted variance
vs. measured (observed) variance. A total of 205 points were
analyzed. The ratio represents the measurement of the
agreement between the predicted and measured uncer-
tainty. Figure 6 shows the frequency of the ratio for
peptide and glycan maps, SE-HPLC and CEx-HPLC,
and overall distributions, respectively. All three distribu-
tions look very similar. The result shows that frequently
(approximately in 50% of cases), the observed variance
of purity measurements is less that 1/10 of the pre-
dicted variance. Larger ratios are less frequent, creating
a characteristic stochastic distribution. This is related to
the fact that a small number of replicates (typically
triplicates) are used to calculate sample variance, which
on some occasions may be significantly different from
the population variance (15).
The results shows that the UBCI model can success-
fully predict the precision (in the form of variance) of
the results based on the information imbedded in chro-
matograms. The estimate of precision corresponds to
the uncertainty under the most unfavorable conditions,
including the highest variability of injection, maximal
numeric integration error, most plausible variability of
the peak width, and most unfavorable contribution of
the noise to the error of peak integration. The model
offers a dynamic live assessment of precision under the
current conditions (consumables, hardware configura-
tion, and software settings) of the method.
Specificity
After successfully addressing method precision dynamically,
we turned our attention to the six remaining performance
characteristics (specificity, linearity, range, accuracy, DL
and QL) to determine whether they can be addressed based
on the current chromatographic information.
The specificity of analytical methods is typically assessed
by examining system interference with the detection and
quantification of analytes. Part of this evaluation is the
determination of protein recovery using equation 1 (see
Materials and Methods) (29,30). With such an approach,
the specificity of the method can be assessed real-time in
every assay, and reflects dynamically the change in status of
consumables (columns and mobile phases) and hardware.
The use of the equation requires the knowledge of the
extinction coefficient for the protein, which can be calculat-
ed from its amino acid composition (31) or determined
experimentally. The extinction coefficient can be considered
constant for a given protein. Therefore, fluctuation of the
area under the peak from the system suitability reference
material can be a good reflection of protein recovery.
Figure 7a shows an example of trending for the total area


























Fig. 5 UBCI Predicted vs. observed variance of purity for individual peaks
on peptide and glycan maps. Solid line represents equivalency between
these two values.
Fig. 6 Distribution of the observed vs. UBCI calculated variance of purity
measurements for different types of methods.
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It should be noted that the extinction coefficient of a
protein may change as the function of pH (29,49). There-
fore, direct comparison of the recovery in the neutral pH
size exclusion method with the recovery in an acidic
reversed-phase separation may not be valid due to differ-
ences in the operating pHs of the methods. The difference
may not necessarily reflect the discrepancy in recovery, but
rather shows pH dependent changes of spectroscopic prop-
erties of the protein.
Accuracy Assessment of Purity Methods
for Biopharmaceuticals
The determination of accuracy for protein purity methods
presents significant challenges. Since it is difficult to establish
orthogonal methods for proteins to measure the same qual-
ity attribute, it is hard to assess the truthfulness of the
accuracy measurements. For example, although SE-HPLC
results can be verified by analytical ultra centrifugation
(AUC) techniques these techniques are based on very differ-
ent first principles, and may not provide comparable results
(50,51). Therefore, in most cases, the accuracy of purity
methods for proteins is inferred when other performance
characteristics meet expectations, which is consistent with
the principles of ICH Q2R1 (6).
Alternatively, accuracy can be assessed by examining the
results of purity calculations for the reference material used
to test system suitability. By convention, the reference stan-
dard is well-characterized material, for which true values of
quality attributes have been established through a very
detailed characterization. Therefore, the ability to recover
these true values during system suitability injections can be
considered as a means for determination of the accuracy of
the method. Figure 7b shows an example of trending accu-
racy for a SE method over several months. Such expression





where PSS is the % purity for individual analyte obtained
during system suitability and PRS is the% purity for individual
analyte obtained during reference standard characterization.
Linearity and Range of Major and Minor Species
Linearity and range are typically assessed in a complex
experiment demonstrating a linear change of peak area with
analyte concentration. Such experiments can be considered
as re-examinations of the Beer-Lambert law for the partic-
ular hardware configuration. Different amounts of mAb
were analyzed by the SE method ranging from 70 μg to
1200 μg. The separation was monitored by a UV detector
at 280 nm, with the linear absorbance range of 2 AU (per
detector specifications (52)). Peak height and peak area were
plotted against the total amount of protein loaded. The
resulting graph is show in Fig. 8. As seen from the graph,
the method comes close to the upper limit of the linear
range at the protein load of approximately 300–400 μg as
monitored by the peak height. At that load, the height for
the main peak approaches the upper specification limit of
the detector, and then levels off. However, the loss of line-
arity is not very apparent from the trace of peak area vs.
load. This is due to increased peak width with larger amount
of injection, causing column and detector saturation. This
indicates that plotting peak height vs. load is enhancing the
assessment of method linearity, and suggests that the meth-
od linearity could be inferred if the tallest analyte peak is
within the working range of the currently used detector. The
peak of the dimer (minor peak) showed linear behavior with
respect to the height and area over the entire range of 70–
1200 μg of total protein load (data not shown). A similar
behavior was observed for other mAbs analyzed by different
methods at different wavelengths (220 and 280 nm). In this
context, the detector’s specification limit could be consid-






































































Fig. 7 Example of trending protein recovery for SE-HPLC method as an
expression of (a) specificity, and (b) accuracy.
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(DL) expressed in mAU can be considered as the lower limit
of the range of the method. Both of these characteristics,
linearity and range, can be assessed real-time for every
hardware configuration and light source.
Detection and Quantification Limits
Practical use of the Detection Limit (DL) is related to the
decision whether to integrate or disregard the peak on the
chromatogram, and is very closely related to the evaluation
of the S/N ratio. ICH guideline Q2R1 defines the DL as the
minimum level of analyte which can be readily detected (6).
For chromatographic methods, a signal to noise ratio of 3 is
generally considered acceptable for estimating the detection
limit. This approach is straightforward and allows for dy-
namic assessment of DL for each individual chromatogram
based on the extracted information about the amplitude
level of the noise.
Assessment of quantification limit (QL) is required for
most analytical methods developed to monitor minor species
that are considered critical quality attributes for the prod-
uct. ICH defines QL as the minimum level of analyte which
can be quantified with acceptable accuracy and precision
(6). Practical use of QL is related to the decision on whether
to report the results of tests. Here we present a challenging
example of QL determination for the acidic peak separated
by a CEx-HPLC method.
Initially, we used the most commonly practiced statistical
approach to estimate the QL for the acidic peak resolved by
cation exchange chromatography (Figure S1c). This approach
is associated with the use of well known equations (6,53):
QL ¼ 10 SD
S
ð18Þ
where SD 0 standard deviation of response, S 0 slope of
calibration curve (sensitivity).
The slope and SD were obtained from linear regression
of the results from a blending experiment by plotting % of
acidic peak vs. the recorded response as integrated area
under the peak at 280 nm (Fig. S4). In all blending experi-
ments, we preserved the total nominal load defined by the
method (120 μg of total protein). The experiment was
performed by mixing our reference standard containing
approximately 5% of the acidic form with other material
containing up to 50% of the acidic form.
The ICH guideline Q2R1 recommends using standard
deviation of the regression line or y-intercept of the regres-
sion line. In this case, values of standard deviation for the
regression line and y-intercepts were very different, and
resulted in the computed QL of 4.7 and 2.8%, respectively
(Table S4). Such large values seem to be “artificially” inflat-
ed (unrealistic), indicating that our method may not be able
to quantify the level of acidic peak in the purified product.
Therefore, we attempted to estimate the QL for the acidic
peak based on S/N ratio, which previously showed a good
agreement with canonical methods (32).
QL ¼ 10 N
S
 P ð19Þ
where N is the peak-to-peak noise, S is the acidic peak
height, and P is the % purity of the peak.
Table S5 shows the results of three experiments per-
formed at the nominal load for a product containing ap-
proximately 5% of the acidic form. The calculation based
on S/N ratio yielded a QL of approximately 0.6%, which is
almost one order of magnitude lower than the previous
assessment. The new value of QL was consistent with the
ICH designation of QL, which requires a S/N ratio of 10 in
order to quantify the peak with confidence. The discrepancy
in estimates could be related to the fact that the blending
experiment was performed in the range significantly above
the QL, and skewed the assessment of SD of the residual
and y-intercept for the regression line. In many situations, it
is extremely difficult (sometimes impossible) to obtain pure
forms of protein variants, which limits the practical range of
the blending experiments. Therefore, dynamic assessment of
the QL based on the S/N ratio (32) offers a quick and
practical assessment of the QL for purity methods.
Using our UBCI model, we estimated the maximal
imprecision of the measurement, assuming that the acidic
peak was at the QL level, 0.6%. Also, we assumed that all
parameters are the same as in the previous experiment
(used to compute dynamic QL). The predicted variance of
purity measurement was 0.0000156, which translates to
7.8% RSD. This is close to the anticipated 10% RSD for
analytes at the QL level, assuming concentration homo-
scedasticity (23). The homoscedasticity means that the
measurement of variance is invariant of analyte concen-
tration. Our model does not require such assumption and
may provide more realistic assessment of maximal impre-
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Fig. 8 Load Linearity for SE-HPLC method designed for mAb.
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Practical Application of the UBCI Model
We have applied all aspects of the UBCI model (current
chromatographic information) to assess uncertainty of the
generated results obtained by a single analytical test
(expected values in all equations were substituted with the
results of a single experiment) We compared these results
with those from historical qualification. The historical qual-
ification was based on ICH Q2R1, and required approxi-
mately 101 independent experiments/injections, while
dynamic assessment of performance is based on information
extracted from a single chromatogram and the system suit-
ability data accompanying the analysis. Figure S1a shows a
SE chromatogram used to extract all the necessary informa-
tion, which includes peak area, peak height, peak width at
half height and at the base, ASTM noise, acquisition rate,
and injection volume. 4 μl injection volumes were used
to derive a 1% RSD of injection variability from the
instrument specifications (46). To assess the specificity,
the chromatogram was compared to the blank chro-
matogram. Table II lists all these parameters and the
resulting output of the expanded UBCI model. We
compared the values of performance characteristics esti-
mated from a single chromatogram with historical qual-
ification data for the method in Table III. The
comparison shows that the UBCI model provides equiv-
alent information about method performance.
DISCUSSION
The ICH Q2 guideline requires that an analytical method
be validated for commercial pharmaceutical and bio-
pharmaceutical applications to demonstrate the method’s
suitability for product disposition and stability testing (if
applicable). Frequently, validation is done only once in the
method’s lifetime. This is particularly of concern when the
future testing is performed on an instrument with different
technical characteristics, in different geographic locations,
using different consumables, different analysts, etc. This
concern is exacerbated by the requirement for modern
pharmaceutical and bio-pharmaceutical companies to seek
regulatory approval in multiple jurisdictions, where the in-
strumentation, consumables, and scientific staff experience
may be very different than in the place where the drug was
developed. These considerations raise questions about the
value of the current format of the validation studies con-
ducted by the industry. Moreover, it is not clear how the
validation data obtained using existing methodologies
should or even could be used toward the assessment of
uncertainty of the future results.
To overcome this limitation, we have developed the
comprehensive UBCI model. We have shown that UBCI
can be successfully applied to assess all performance char-
acteristics of purity methods. This assessment can be per-
formed live based on the current information embedded in
the chromatogram or electrophoregram of the tested sample
and from the accompanying system suitability data. In
Table III we compare the results of the live assessment of
uncertainty with historical qualification results, which were
generated on an equivalent instrument approximately a
year prior to performing the test analysis. We showed that
the performance assessment obtained using UBCI correlates
well with the historical data acquired on one brand of
instrumentation. The historical value of RSD for high mo-
lecular weight (HMW) specie (5.60%) is notably lower than
the predicted precision (16.57%). This is related to the fact
that UBCI model predicts the upper bound of precision,
Table II Parameters Extracted from Single Chromatogram
Parameter of the peak HMW (pre-peak 1) Dimer ( pre-peak 2) Main
Input Area [mAU*s] 28.118 384.102 22703.904
Height [mAU] 0.801 10.185 871.261
Wight at half height [min] 0.543 0.550 0.380
Width at the base [min] 1.119 1.853 5.627
Variability of peak width at the base [%] RSD03% ( see Fig. 4)
ASTM noise [mAU] 0.00482
Acquisition rate [Hz] 2.5
Instrument Injection RSD [%] 1% for less than 5 μl (4 μl was injected)- see text
Output Purity 0.0012 (0.12%) 0.0166 (1.62%) 0.9822(98.22%)
Variance of area (eq.16) 21.7388 63.2849764 14434
Variance of purity (eq. 5) 4.06E-08 1.22E-07 1.62E-07
DL [mAU] 0.01446 0.01446 N/A
QL [%] (eq.19) 0.00007 (0.007%) 0.00008 (0.008%) N/A
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which could make the difference more apparent for small
and broad peaks. Also, linearity, range, and accuracy were
expressed differently than for the historical data.
This live assessment approximates the maximal uncer-
tainty of the measurement associated with the actual con-
ditions of analysis (test). The obtained precision corresponds
to the uncertainty under the most unfavorable conditions,
including the highest variability of injection, maximal nu-
meric integration error, expected variability of the peak
width, and the most unfavorable contribution of the noise.
UBCI shows that the uncertainty of results is not only a
function of the method (composition of the mobile phase,
gradient, flow rate, temperature), but also is influenced by
the hardware associated with the execution of the method
(pump pulsation, detector range, status of the lamp, etc.),
and the software settings used to acquire the output in the
form of chromatograms. Information about these parame-
ters can be extracted from individual chromatograms; there-
fore, the assessment of method performance characteristics
(uncertainty) can be performed real-time, which can be
considered as a ‘live validation’ associated with each indi-
vidual test result. We demonstrated that the model is suit-
able for well-resolved peaks, and will require further
refinement for poorly resolved, overlapping peaks (with
resolution <1). We intend to continue our effort in this
direction. Such refined model may have practical utility in
improving the assessment of uncertainty of results generated
by ion exchange methods, which typically display poorly
resolved peaks.
The most essential aspect of assessing the uncertainty of
purity measurements is the precision. In our model, the
variance of purity measurements is a function of the repro-
ducibility of the injector, numerical integration, and base-
line noise, which is reflected in three terms, as shown in
equation 16. Analysis of the equation offers multiple ways to
minimize the variance of purity measurements. The first
term of the equation can be minimized by selecting a HPLC
instrument with low imprecision of injection. The second
term of the equation can be zeroed if the variance of the
integration domain is equal to zero, or can be minimized
with the use of consistent integration practices. Additional
factors minimizing the influence of the second term include
a narrow peak width at half height (sharper peaks), and
an optimal acquisition rate. A faster acquisition rate will
minimize the contribution of this term but it will inten-
sify the noise, which will increase the value of the next
term. The influence of the third term can be minimized
by decreasing the baseline noise and the width of the
integration domain (48,54), which is an expression of the
S/N ratio for Gaussian-shaped peaks. Overall, high fidel-
ity HPLC, consistent integration practices, and a high
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The UBCI model shows that the most probable variance
of experiments is 1/10 of the variance predicted by the
UBCI model, even when the measurements are conducted
on the same instrument by the same analyst. This has been
corroborated by the F-test experiment, which shows that in
21% of cases, the repeat of the experiment executed under
the same conditions can differ by an order of magnitude or
more. Therefore, one should use extreme caution in using
precision as an acceptance criterion in studies involving
method equivalency, technology transfer, etc. Additionally,
this suggests that the value of precision obtained during
method qualification or validation should be treated with a
healthy dose of “skepticism” when assessing future
uncertainty.
Laboratories that work in a GMP environment are re-
quired to produce extensive documentation to show that the
method is suitable. Pharmaceutical and bio-pharmaceutical
companies “religiously” adhere to these requirements,
which inundates industry with an avalanche of validation
work that has questionable value toward the future assess-
ment of uncertainty. Our UBCI model of uncertainty pro-
vides an alternative that has the potential to reduce the work
required to demonstrate method suitability and, in turn,
provide greater assurance of the validity of the results from
the specific analysis in real time.
Recently, the industry has begun adopting the concept of
science based Quality by Design (QbD) to several aspects of
the pharmaceutical lifecycle (55). The basic concepts are
described in ICH guidelines Q8, Q9 and Q10 (56–58).
Our methodology is consistent with the spirit of QbD.
Perhaps the time is right for the industry to consider the
use of a combination of sound science and reasonable risk
assessment to change the current practice of the retrospec-
tive use of method validation to the new paradigm of live
validation of purity methods based on the current informa-
tion embedded in the chromatogram. While the proposed
model may be contentious, as it challenges the way in which
method qualification and validation have been traditionally
performed, the model is worthy of consideration because it
addresses some of the existing limitations of the current
method qualification/validation paradigm.
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